Literature DB >> 22455658

Effect of topically applied epithelial sodium channel inhibitors on tear production in normal mice and in mice with induced aqueous tear deficiency.

William R Thelin1, M Ross Johnson, Andrew J Hirsh, Claire L Kublin, Driss Zoukhri.   

Abstract

PURPOSE: Dry eye syndromes affect a significant proportion of the population worldwide with reported prevalence ranging from 6% to more than 34%. Patients with dry eye can experience intense pain due to eye irritation, gritty/scratchy feeling in the eyes, blurry vision, and light sensitivity. Available treatments for dry eye syndromes remain mainly palliative. The purpose of the present study was to test the hypothesis that inhibiting sodium absorption via the epithelial sodium channel (ENaC) will increase ocular hydration in both normal as well as in animals with experimentally induced dry eye.
METHODS: ENaC inhibitors were dissolved in an aqueous buffer that mimics the composition of tears and were applied topically to the ocular surface of isoflurane-anesthetized mice. The effect of ENaC inhibitors was compared with that of the secretagogue uridine triphosphate (UTP; 1%), a purinergic receptor agonist which was shown to increase tear volume in animals. Tear production was measured for 10 s using phenol red-impregnated cotton threads. Fluorescein staining that assesses ocular surface damage was performed at baseline and then at days 1, 2, and 3 after the induction of dry eye in mice.
RESULTS: Our data show that the inhibition of ENaC led to a time- and concentration-dependent increase in tear volume in normal mice. The effect of ENaC inhibition after a single application outperformed UTP, as it was long-lasting with tear volume still above baseline values 8 h postdosing. ENaC inhibition, which led to increased tear production, improved fluorescein scores in our dry eye model, when compared with nontreated or animals treated with buffer or UTP.
CONCLUSION: We conclude that the inhibition of ENaC provides long-lasting increases in ocular surface hydration and that ENaC blockers could provide an effective new therapy for chronic dry eye.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22455658      PMCID: PMC3406319          DOI: 10.1089/jop.2011.0157

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  35 in total

Review 1.  Use of muscarinic agonists in the treatment of Sjögren's syndrome.

Authors:  R I Fox; Y Konttinen; A Fisher
Journal:  Clin Immunol       Date:  2001-12       Impact factor: 3.969

2.  Rabbit conjunctival epithelium transports fluid, and P2Y2(2) receptor agonists stimulate Cl(-) and fluid secretion.

Authors:  Y Li; K Kuang; B Yerxa; Q Wen; H Rosskothen; J Fischbarg
Journal:  Am J Physiol Cell Physiol       Date:  2001-08       Impact factor: 4.249

Review 3.  Classification criteria for Sjögren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group.

Authors:  C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman
Journal:  Ann Rheum Dis       Date:  2002-06       Impact factor: 19.103

Review 4.  Effect of inflammation on lacrimal gland function.

Authors:  Driss Zoukhri
Journal:  Exp Eye Res       Date:  2005-11-23       Impact factor: 3.467

Review 5.  The normal tear film.

Authors:  John M Tiffany
Journal:  Dev Ophthalmol       Date:  2008

6.  Efficacy of 3 different artificial tears for the treatment of dry eye in frequent computer users and/or contact lens users.

Authors:  Gil Calvão-Santos; Cristina Borges; Sandrina Nunes; José Salgado-Borges; Lilianne Duarte
Journal:  Eur J Ophthalmol       Date:  2011 Sep-Oct       Impact factor: 2.597

7.  Potential difference measurements of ocular surface Na+ absorption analyzed using an electrokinetic model.

Authors:  Marc H Levin; Jung Kyung Kim; Jie Hu; A S Verkman
Journal:  Invest Ophthalmol Vis Sci       Date:  2006-01       Impact factor: 4.799

8.  The effect of topical amiloride eye drops on tear quantity in rabbits.

Authors:  Shuya Hara; Akihiro Hazama; Masao Miyake; Takashi Kojima; Yasumasa Sasaki; Jun Shimazaki; Murat Dogru; Kazuo Tsubota
Journal:  Mol Vis       Date:  2010-11-04       Impact factor: 2.367

Review 9.  Prevalence and risk factors associated with dry eye symptoms: a population based study in Indonesia.

Authors:  A J Lee; J Lee; S-M Saw; G Gazzard; D Koh; D Widjaja; D T H Tan
Journal:  Br J Ophthalmol       Date:  2002-12       Impact factor: 4.638

Review 10.  Dry eye: diagnosis and current treatment strategies.

Authors:  Paul D O'Brien; Louis M T Collum
Journal:  Curr Allergy Asthma Rep       Date:  2004-07       Impact factor: 4.919

View more
  8 in total

1.  Nanomolar-Potency Aminophenyl-1,3,5-triazine Activators of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Chloride Channel for Prosecretory Therapy of Dry Eye Diseases.

Authors:  Sujin Lee; Puay-Wah Phuan; Christian M Felix; Joseph-Anthony Tan; Marc H Levin; Alan S Verkman
Journal:  J Med Chem       Date:  2017-01-31       Impact factor: 7.446

2.  Topical administration of ambroxol eye drops augments tear secretion in rabbits.

Authors:  Li Yu; Dhruva Bhattacharya; Zhenhan Wang; Mingwu Wang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2021-01-29       Impact factor: 3.117

Review 3.  Age-related Defects in Ocular and Nasal Mucosal Immune System and the Immunopathology of Dry Eye Disease.

Authors:  Marjan Farid; Anshu Agrawal; Daniel Fremgen; Jeremiah Tao; He Chuyi; Anthony B Nesburn; Lbachir BenMohamed
Journal:  Ocul Immunol Inflamm       Date:  2014-12-23       Impact factor: 3.070

4.  Small-molecule CFTR activators increase tear secretion and prevent experimental dry eye disease.

Authors:  Alyssa M Flores; Scott D Casey; Christian M Felix; Puay W Phuan; A S Verkman; Marc H Levin
Journal:  FASEB J       Date:  2016-02-03       Impact factor: 5.191

5.  Do Cyclosporine A, an IL-1 Receptor Antagonist, Uridine Triphosphate, Rebamipide, and/or Bimatoprost Regulate Human Meibomian Gland Epithelial Cells?

Authors:  Wendy R Kam; Yang Liu; Juan Ding; David A Sullivan
Journal:  Invest Ophthalmol Vis Sci       Date:  2016-08-01       Impact factor: 4.799

6.  Lacrimal Gland Repair Using Progenitor Cells.

Authors:  Anastasia Gromova; Dmitry A Voronov; Miya Yoshida; Suharika Thotakura; Robyn Meech; Darlene A Dartt; Helen P Makarenkova
Journal:  Stem Cells Transl Med       Date:  2016-08-15       Impact factor: 6.940

Review 7.  Experimental Pharmacotherapy for Dry Eye Disease: A Review.

Authors:  Monica Baiula; Santi Spampinato
Journal:  J Exp Pharmacol       Date:  2021-03-23

8.  Ocular Surface Potential Difference Measured in Human Subjects to Study Ocular Surface Ion Transport.

Authors:  Neel D Pasricha; Alex J Smith; Marc H Levin; Julie M Schallhorn; Alan S Verkman
Journal:  Transl Vis Sci Technol       Date:  2020-10-15       Impact factor: 3.283

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.